AMPE News and Press, Ampio Pharmaceuticals Inc. From 04/02/20

ENGLEWOOD, Colo. , April 2, 2020 /PRNewswire/ --  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today tha...

Are These 3 Penny Stocks On Your List This Week? Penny stocks continue to flourish while the broader markets seesaw on April 1. Big names like Apple and Boeing are down big to start the second quarter. But that hasn’t put one bit of pause to the momentum that small-cap and micro-cap s...

Ampio Pharmaceuticals (NYSEMKT: AMPE ) has suspended patient enrollment in its Phase 3 clinical trial of Ampion ("AP-013") for the treatment of severe osteoarthritis of the knee, due to the COVID-19 pandemic. More news on: Ampio Pharmaceuticals, Inc., Healthcare stocks news, Stocks ...

ENGLEWOOD, Colo. , March 24, 2020 /PRNewswire/ --  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the "Company") , a pre-revenue   development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clinical trial of Ampion ("AP...

Ampio Pharmaceuticals (NYSEMKT: AMPE ) is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 induced Acute Respiratory Distress Syndrome ("ARDS"), an immediately life-threatening condition. More news on: Ampio Pharma...

ENGLEWOOD, Colo. , March 24, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions for which limited tr...

Ampio Pharmaceuticals Inc. (NYSE American: AMPE) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “AMPE continues to swiftly enroll patients into its AP-013 confirmatory Phase 3 trial in severe osteoarthritis of the knee (OAK KL4)...

ENGLEWOOD, Colo. , Feb. 21, 2020 /PRNewswire/ --   Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment ("SPA") Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampion ...

Will These Penny Stocks Be On Your Friday Watch List? With the short week coming to an end, some traders will take an inventory of the last few days and assess a few things. First and foremost, taking into account any losses incurred from penny stocks, for instance. If you are doing this right...

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Neutral rating and $33 (4% upside) price target at H.C. Wainwright. More news on: Aimmune Therapeutics, Inc., Ampio Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...